Glycomimetic

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Retrieved on: 
일요일, 12월 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acute myeloid leukemia, LDAC, Safety, National Cancer Institute, ASH, Leukemia, Cellular, IIT, Cytogenetics, HCT, Pedal, Patient, Inflammation, Male, Cytarabine, Biobank, University, Transplant, AML, MD Anderson Cancer Center, Cancer, Society, Myelodysplastic syndrome, Cladribine, Haematopoietic system, Venetoclax, Pharmaceutical industry, Glycomimetic

“These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.

Key Points: 
  • “These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
    This Phase 1b/2 clinical trial evaluated safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and LDAC in patients with ts-AML.
  • This rare, high-risk study population is defined by prior chemotherapy treatment of a previous hematologic disorder, such as myelodysplastic syndrome.
  • Study investigators concluded these data support this low-risk approach to marrow blast reduction and disease control in preparation for HCT.

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Retrieved on: 
목요일, 11월 9, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Conference, Online shopping, Cryptocurrency, Glycomimetic

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m.
  • ET.
  • A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations .
  • An archived recording will be available for 30 days following the event.

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Retrieved on: 
금요일, 11월 3, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, MD Anderson Cancer Center, Neurotransmission, NCI, Food, Cytarabine, Alliance for Clinical Trials in Oncology, Inflammation, Safety, European Medicines Agency, Sickle cell disease, Volunteering, ASH, Pharmacokinetics, Cancer, National Cancer Institute, PIP, NDA, Cladribine, Patient, Food and Drug Administration, AML, D, Pharmaceutical industry, Glycomimetic

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
  • With the addition of the time-based analysis, the company expects topline results by the end of Q2 2024.
  • Third Quarter 2023 Financial Results:
    Cash position: As of September 30, 2023, GlycoMimetics had cash and cash equivalents of $49.4 million as compared to $47.9 million as of December 31, 2022.
  • A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.

Korro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer

Retrieved on: 
수요일, 10월 25, 2023
MedImmune, Security (finance), IND, RNA, Doctor of Philosophy, MBA, Protein, Growth, Disease, Treasurer, Prospectus, Biology, Glycomimetic, HDAC, Frequency, AATD, Alpha-1 antitrypsin deficiency, Therapy, Patient, Investigational New Drug, Audit committee, Management, Shareholder

Korro Bio expects to close both the financing and merger promptly after the required approvals are obtained from Frequency’s stockholders.

Key Points: 
  • Korro Bio expects to close both the financing and merger promptly after the required approvals are obtained from Frequency’s stockholders.
  • This appointment will be effective upon completion of the merger.
  • Mr. Pearson has over 30 years of healthcare experience and has served as Chief Executive Officer of Carrick Therapeutics since July 2019.
  • Prior to that, Mr. Chappell served as Chief Executive Officer of Rasio Therapeutics, Inc. and Perceptive Navigation, LLC.

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Retrieved on: 
금요일, 10월 20, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Glycomimetic

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates with the goal of developing transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m.
  • To access the call by phone, please go to this registration link and you will be provided with dial in details.
  • Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
  • A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

Retrieved on: 
월요일, 10월 23, 2023
American Cancer Society, Harvard–MIT Program in Health Sciences and Technology, Bachelor of Arts, Harvard Medical School, Brigham and Women's Hospital, IMGN, Genzyme, Biotechnology, ImmunoGen, MD, Drug, Harvard College, Senior, Medicine, Synageva, CBAB, ACS, LSE, Cancer, Hospital, BPMC, SAN, Management, Glycomimetic

SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).

Key Points: 
  • SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
  • "We are pleased to welcome Dr. Goldberg as the 9th independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "Mark brings valuable clinical expertise in oncology, and his extensive biotechnology executive experience will be an asset to Anixa.
  • Dr. Goldberg received his Bachelor of Arts degree from Harvard College and his medical degree from the Harvard-MIT Program in Health Sciences and Technology.

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 9월 28, 2023
APLM, PIPE, NDA, Lung cancer, Mutation, NSCLC, Brain, Trial of the century, AML, Patient, Investment, Cancer, MET, National Medical Products Administration, R, Glycomimetic, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, NMPA, Food, Pharmaceutical industry, Life insurance, Cryptocurrency, Fine chemical, Security (finance)

FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced its financial results for the six months ended June 30, 2023, and provided a corporate update.

Key Points: 
  • ET
    FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced its financial results for the six months ended June 30, 2023, and provided a corporate update.
  • In March 2023, the Company raised $23.7 million in a private placement in public equity (PIPE) financing, before transaction expenses.
  • Apollomics’ management team will host a conference call and webcast Monday, October 2, 2023 at 8:30 a.m.
  • ET to discuss the financial results and provide a corporate update.

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Retrieved on: 
수요일, 9월 6, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Safety, Inflammation, Sickle cell disease, Volunteering, Pharmacokinetics, Cancer, Pharmaceutical industry, Glycomimetic

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced dosing of the first cohort of healthy volunteers in a Phase 1a study of GMI-1687 to evaluate safety, tolerability, and pharmacokinetics.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced dosing of the first cohort of healthy volunteers in a Phase 1a study of GMI-1687 to evaluate safety, tolerability, and pharmacokinetics.
  • “We are excited to progress our pipeline and advance GMI-1687, a highly potent, second-generation E-selectin antagonist, into clinical development, “said Harout Semerjian, Chief Executive Officer of GlycoMimetics.
  • Eligible subjects will receive a single dose of GMI-1687 or placebo (6:2 ratio) via subcutaneous injection.
  • Safety, tolerability, and pharmacokinetics of up to five dose levels (3.3, 10, 20, 40, and 80 mg) will be evaluated.

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
화요일, 9월 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Cryptocurrency, Broadcasting, Glycomimetic

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m.
  • ET.
  • A live webcast of the presentation will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations .
  • An archived recording will be available for 30 days following the event.

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
목요일, 8월 17, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Common stock, Employment, Compensated emancipation, Security (finance), Glycomimetic

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Key Points: 
  • GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock option award to purchase an aggregate of 110,000 shares to Gaetano Bonifacio, M.D., the Company’s new Vice President, Global Medical Affairs.
  • The award was granted as an inducement equity award outside of the Company’s Amended and Restated 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4) and was made as an inducement material to the acceptance of employment with the Company by the new employee.
  • The option grant has an exercise price of $1.65 per share, the closing price of the Common Stock on the date of grant, and is subject to the terms and conditions of a stock option agreement and the GlycoMimetics, Inc.
  • Amended and Restated Inducement Plan, which provides for the granting of stock options and other equity awards to new employees.